Este dividendul Siegfried Holding sigur?
Siegfried Holding crește dividendul de 8 ani.
În ultimii 10 ani, Siegfried Holding a crescut aceasta cu 10,976 % anual.
Pe o perioadă de 5 ani, distribuția a crescut cu 7,215 %.
Analiștii estimează pentru anul fiscal curent o creștere de Creșterea dividendelor% de 8,268%.
Siegfried Holding Aktienanalyse
Ce face Siegfried Holding?
The Siegfried Holding AG is a Swiss pharmaceutical company based in Zofingen, which operates worldwide. The company's history dates back to 1873, when the pharmacist and chemist Franz von Siegfried founded the "First Aid Pharmacy". Over the years, the company has developed into an important producer of pharmaceutical ingredients.
The business model of Siegfried Holding AG is based on the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. The products are used in various areas, such as veterinary medicine, human medicine, or the chemical industry.
Siegfried operates various divisions that focus on different segments of the value chain. These divisions include production, contract development and manufacturing (CDMO), and commercial products. In the production division, the company produces pharmaceutical ingredients and intermediate products. The CDMO business offers custom development and manufacturing services for the pharmaceutical and biotech industry. In the commercial products division, finished products such as cough medicine, antidepressants, or blood pressure reducers are distributed.
Among the products offered by Siegfried are the active ingredient carbamazepine, which is used as an anticonvulsant and for the treatment of bipolar disorder. Another active ingredient is acetaminophen, which is used as a painkiller and fever reducer. Siegfried also produces the active ingredient sotalol, which is used to treat heart rhythm disorders.
In the context of the CDMO business, Siegfried also develops and produces custom products for the pharmaceutical and biotech industry. This includes the manufacturing of clinical trial preparations, the implementation of process developments, and scale-up productions of active ingredients and finished products.
In recent years, Siegfried Holding AG has made several acquisitions to expand its business and strengthen its market presence. In 2016, the company acquired Bexbach-based Saltigo GmbH, a specialist in the production of customer-specific fine chemicals. Two years later, Siegfried acquired the active ingredient production business of Alcami, a US pharmaceutical company.
In summary, it can be said that Siegfried Holding AG is an established Swiss pharmaceutical company specializing in the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. In recent years, the company has made several acquisitions to expand its market presence and diversify its business. Siegfried Holding este una dintre cele mai populare companii pe Eulerpool.com.Planurile de economii în acțiuni oferă o oportunitate atractivă pentru investitori de a construi avere pe termen lung. Unul dintre principalele avantaje este așa-numitul efect de medie a costurilor: investind regulat o sumă fixă în acțiuni sau fonduri de acțiuni, se cumpără automat mai multe părți când prețurile sunt scăzute și mai puține când sunt ridicate. Acest lucru poate duce la un preț mediu pe acțiune mai avantajos pe parcursul timpului. În plus, planurile de economii în acțiuni permit și investitorilor cu bugete mici accesul la acțiuni scumpe, deoarece pot participa cu sume mici. Investiția regulată promovează, de asemenea, o strategie de investiții disciplinată și ajută la evitarea deciziilor emoționale, cum ar fi cumpărarea sau vânzarea impulsivă. În plus, investitorii beneficiază de potențiala creștere în valoare a acțiunilor, precum și de distribuirile de dividende care pot fi reinvestite, amplificând efectul de dobândă compusă și astfel creșterea capitalului investit.